Expectant mothers who take the popular anti-epileptic drug valproate during pregnancy should be aware that there is an increased risk for their child developing autism compared with children of women who did not take the epilepsy drug, according to a recently published Danish study.
Valproate is a drug used for the treatment of epilepsy and other neuropsychological disorders. Maternal use during pregnancy was associated with a significantly increased risk of autism in offspring, according to a study in the April 24 issue of JAMA.
The population-based study included all children born alive in Denmark from 1996 to 2006. National registers were used to identify children exposed to valproate during pregnancy and diagnosed with autism spectrum disorders, (childhood autism [autistic disorder], Asperger syndrome, atypical autism, and other or unspecified pervasive developmental disorders).
The study involved data on 655,615 children born to 428,407 mothers between 1996 and 2006, including 508 children exposed to valproate during pregnancy. Over follow-up to a mean age of 8.8 years, 5,437 children were diagnosed with autism spectrum disorder, including 2,067 with childhood autism.
Data were analyzed and adjusted for potential factors that could have influenced the outcomes; such as maternal age at conception, paternal age at conception, parental psychiatric history, gestational age, birth weight, sex, congenital malformations, and parity. Children were followed up from birth until the day of autism spectrum disorder diagnosis, death, emigration, or December 31, 2010, whichever came first.
Among children exposed to valproate, the risk for autism spectrum disorder was 2.9-fold greater, and the risk for childhood autism was 5.1-fold greater than among unexposed children (absolute 14-year risk: 4.4 vs 1.5%; 2.5 vs 0.5%, respectively).
The risks for autism spectrum disorder and childhood autism were also 2.2-fold, and 5.6-fold greater, respectively, in exposed children than in children of mothers who stopped taking valproate at least 30 days before conception.
Writing in JAMA, the study authors stress that it is important to carefully balance these concerns against the benefits of valproate in epilepsy control.
Jakob Christensen, Ph.D., of Aarhus University Hospital, Aarhus, Denmark, and colleagues evaluated the association between maternal use of valproate during pregnancy and the risk of autism spectrum disorder and childhood autism in offspring.
“Because autism spectrum disorders are serious conditions with life-long implications for affected children and their families, even a moderate increase in risk may have major health importance,” said Christensen and colleagues.
“Still, the absolute risk of autism spectrum disorder was less than 5%, which is important to take into account when counseling women about the use of valproate in pregnancy.”
However, in an accompanying editorial, Kimford Meador and David Loring, both from Emory University in Atlanta, Georgia, USA, say that current rates of valproate prescriptions among girls and women of reproductive age indicate that the risks of fetal exposure are not sufficiently taken into account.
“This raises concern as to whether these women are receiving adequate information for informed consent based on a full understanding of the treatment risks and alternative therapies,” they write.
Alternative medications should be used wherever possible, and women should be informed of the risks associated with valproate even if they are not currently planning to conceive, they conclude.
“Anti-epileptic drug exposure during pregnancy has been associated with an increased risk for congenital malformations and delayed cognitive development in the offspring, but little is known about the risk of other serious neuropsychiatric disorders,” according to background information in the article.
The authors caution that these findings must be balanced against the treatment benefits for women who require valproate for epilepsy control.
Questions About The Article?
Hot Category Topics
- Actos Bladder Cancer (10)
- Antidepressant Birth Defects (11)
- Avodart Prostate Cancer (5)
- Crestor Muscle Damage (6)
- Darvon Darvocet Heart Arrhythmia (1)
- Depakote Seizures Birth Defects (2)
- Drug Lawsuits (112)
- Drug Recalls (28)
- Drug Safety News (439)
- Featured (5)
- Latest Investigations (48)
- Medical Device Lawsuits (37)
- Medical Device News (82)
- Medical Device Recalls (18)
- Metal-On-Metal Hip Implants (2)
- Mirena Lawsuits (6)
- Morcellator Cancer (3)
- OsmoPrep Kidney Damage (6)
- Propecia Side Effects (1)
- Recalls (30)
- Shoulder Pain Pumps (1)
- Testosterone Stroke Heart Attack (4)
- Topamax Birth Defects (6)
- Vaccine News (7)
- Vaginal Mesh Erosion (18)
- Xarelto (6)